Abstract | BACKGROUND: METHODS AND RESULTS: In the Danish Investigations of Arrhythmia and Mortality ON Dofetilide ( DIAMOND) studies, 506 patients were in atrial fibrillation (AF) or atrial flutter (AFl) at baseline. Over the course of study, cardioversion occurred in 148 (59%) dofetilide- and 86 (34%) placebo-treated patients. In these patients, the probability of maintaining sinus rhythm for 1 year was 79% with dofetilide versus 42% with placebo ( P < 0.001). Dofetilide had no effect on all-cause mortality, but restoration and maintenance of sinusrhythm (independent of study treatment) was associated with a significant reduction in mortality (risk ratio [RR], 0.44; 95% CI, 0.30 to 0.64; P < 0.0001). In addition, dofetilide therapy was associated with a significantly lower risk ratio versus placebo for either all-cause (RR, 0.70; 95% CI, 0.56 to 0.89; P < or = 0.005) or congestive heart failure (RR, 0.69; 95% CI, 0.51 to 0.93; P < or = 0.02) rehospitalization. CONCLUSIONS:
Dofetilide is safe and increases the probability of obtaining and maintaining sinus rhythm in patients with structural heart disease. The present study suggests that restoration of sinus rhythm--on placebo or dofetilide--is associated with improved survival.
|
Authors | Ole Dyg Pedersen, Bente Brendorp, Hanne Elming, Steen Pehrson, Lars Køber, Christian Torp-Pedersen |
Journal | Cardiac electrophysiology review
(Card Electrophysiol Rev)
Vol. 7
Issue 3
Pg. 220-4
(Sep 2003)
ISSN: 1385-2264 [Print] United States |
PMID | 14739717
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Anti-Arrhythmia Agents
- Phenethylamines
- Sulfonamides
- dofetilide
|
Topics |
- Anti-Arrhythmia Agents
(therapeutic use)
- Atrial Fibrillation
(complications, drug therapy, prevention & control)
- Double-Blind Method
- Humans
- Multicenter Studies as Topic
- Phenethylamines
(therapeutic use)
- Randomized Controlled Trials as Topic
- Retrospective Studies
- Sulfonamides
(therapeutic use)
- Ventricular Dysfunction, Left
(complications, mortality)
|